Bicara Therapeutics Inc. (BCAX)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $9.75
- As of
Kresmion compiles this page from BCAX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Bicara Therapeutics Inc. (BCAX): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-09.
See the full BCAX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BCAX on one page. Preview it with sample data, then open it live with a free account.
Preview the BCAX dossierActive events for BCAX
- mediumEarnings below estimates
Q3-2026: Missed consensus by 23.0%, EPS $-1.04 vs $-0.8454 estimate
- high13F: funds added
3 tracked funds increased BCAX this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +273% to BCAX (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +758% to BCAX (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +67% to BCAX (2026Q2)
FREE, NO ACCOUNT
Every event on BCAX, as it fires
You are seeing 5 of 11 events recorded on BCAX since 2026-06-15.
The five above landed across 3 days. The other 6 were recorded on 2 other days. 6 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, BCAX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
More data on BCAX
BCAX against its peers
BCAX's return on equity of -34.4% ranks in the 74th percentile of 20 Biotechnology sub-industry peers, fiscal periods ending between 2025-03-31 and 2025-12-31.
| Metric | BCAX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 14.1M | n/a | 9 |
| Operating margin | n/a | -360.5% | n/a | 8 |
| Net margin | n/a | -325.4% | n/a | 8 |
| Return on equity | -34.4% | -46.8% | 74 | 20 |
| 1 year | -35.8% | 8.9% | 21 | 20 |
Peers (21): HELP, IMMX, KURA, DSGN, OLMA, WVE, FDMT, AVBP, ABUS, CGEM, ANNX, DBVT, CLYM, GERN, ACHV, NVCT, XOMA.D, SGMT, SRZN, OBIO, FTH. Left out: ANL (period gap), APMD (no annual filing), ATTO (no annual filing), ETRA (no annual filing). Fiscal periods ending between 2025-03-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (BCAX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in BCAX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on BCAX in the last 180 days.
Upstream: SEC EDGAR filings for BCAX
Kresmion, "Bicara Therapeutics Inc. (BCAX) institutional holdings and SEC filings", data as of 2026-11-13, https://kresmion.com/research/BCAX. Upstream data: SEC EDGAR filings for BCAX.
Link to this data (HTML):
<a href="https://kresmion.com/research/BCAX">Bicara Therapeutics Inc. (BCAX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow BCAX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to BCAX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.